Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring adult anaplastic oligodendroglioma, adult mixed glioma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed supratentorial pure or mixed anaplastic oligodendroglioma Unifocal or multifocal disease Prior suspected or proven low-grade glioma eligible provided biopsy reveals pure or mixed anaplastic oligodendroglioma that has not been previously treated with radiotherapy and/or chemotherapy No equivocal oligodendroglial element No tumors predominantly located in the posterior fossa (i.e., brainstem or cerebellum) No spinal cord tumors No evidence of spinal drop metastasis or spread to noncontiguous meninges PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: Zubrod 0-1 Life expectancy: More than 12 weeks Hematopoietic: Absolute granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 2 times normal Aspartate aminotransferase (AST) no greater than 3 times normal Alkaline phosphatase no greater than 2 times normal Renal: Creatinine no greater than 1.5 times normal Other: No active infection No other medical problems that would preclude study participation No other malignancy within the past 3 years except carcinoma in situ of the cervix or nonmelanoma skin cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior chemotherapy for this malignancy No prior temozolomide Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy to the brain, head, or neck Surgery: At least 14 days since prior surgery requiring general anesthesia
Sites / Locations
- Mobile Infirmary Medical Center
- Foundation for Cancer Research and Education
- CCOP - Mayo Clinic Scottsdale Oncology Program
- Shands Cancer Center at the University of Florida Health Science Center
- Mayo Clinic
- University of Miami Sylvester Cancer Center
- Baptist Hospital of Miami
- Mayo Clinic Cancer Center
- CCOP - Kansas City
- Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha
- Monmouth Medical Center
- Wayne Memorial Hospital, Inc.
- Rutherford Hospital
- CCOP - Southeast Cancer Control Consortium
- Akron City Hospital
- Adena Regional Medical Center
- CCOP - Columbus
- Riverside Methodist Hospital
- Mount Carmel West Hospital
- Grady Memorial Hospital
- Fairfield Medical Center
- Strecker Cancer Center at Marietta Memorial Hospital
- Licking Memorial Hospital
- CCOP - Toledo Community Hospital
- CCOP - Columbia River Oncology Program
- Mercy Hospital of Pittsburgh
- Anderson Area Cancer Center
- Cottonwood Hospital Medical Center
- McKay-Dee Hospital Center
- Utah Valley Regional Medical Center - Provo
- Dixie Regional Medical Center
- University of Utah Health Sciences Center
- LDS Hospital
- University Cancer Center at University of Washington Medical Center
- Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
- University of Wisconsin Comprehensive Cancer Center
- CCOP - Marshfield Clinic Research Foundation
- Medical College of Wisconsin Cancer Center
- Saint John Regional Hospital
Arms of the Study
Arm 1
Experimental
Pre-RT temozolomide, RT plus temozolomide
Pre-radiation therapy (RT) temozolomide, RT plus temozolomide